from Wiktionary, Creative Commons Attribution/Share-Alike License

  • n. A particular antipsoriatic drug.


from Wiktionary, Creative Commons Attribution/Share-Alike License

-li- +‎ -zu- +‎ -mab


  • Raptiva, which is also known as efalizumab, is an immunosuppressant drug used to treat and prevent psoriasis, a chronic, non-contagious autoimmune disease which causes excess skin production and joint pain.

    WebWire | Recent Headlines

  • With regard to its psoriasis drug Raptiva efalizumab, a chain of unfortunate events began when Xoma's management at the time miscalculated the firm's financial capability with regard to co-developing this drug with Genentech.

    Xoma and Elan: A Tale of Two Mismanaged Biotech Companies, Part 1 - Seeking Alpha

  • Chamian F, Abello MV, Fuentes-Duculan J, Lin SL, et al. (2005) Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a).

    PLoS ONE Alerts: New Articles

  • Obstacles to Stelara adoption include concerns about long term safety which are exacerbated by the recent withdrawal of Genentech/Xoma's Raptiva (efalizumab) due to PML.


  • FDA officials said prescribers are being asked not to initiate new Raptiva (efalizumab) treatment and begin discussions with patients using the medication on how to move to alternative psoriasis therapies.

    Latest News -

  • Etanercept and efalizumab for the treatment of adults with psoriasis.

    PR Newswire: All Releases

  • Genentech estimated that approximately 2,000 patients in the United States may currently be using Raptiva (efalizumab) for chronic plaque psoriasis.


  • April 8, 2009 - Uniondale, New York -- Mark & Associates, P.C., a leading nationwide personal injury law firm, applauds Genentech's decision to suspend sales of the psoriasis drug Raptiva (efalizumab) in the United States.

    WebWire | Recent Headlines

  • April 8, 2009 -- Today, Genentech, the manufacturer of the psoriasis drug Raptiva (efalizumab), announced that it has begun a voluntary, phased withdrawal of the product from the U.S. market.


  • RAPTIVA (r) (efalizumab) Collaboration with Genentech and Merck Serono -- According to Genentech and Merck Serono SA, worldwide sales of RAPTIVA (r) in the third quarter of 2008 were



Log in or sign up to get involved in the conversation. It's quick and easy.